Noncarbohydrate Inhibitors of Sialic Acid-Binding Immunomodulatory-Type Lectin-7 (Siglec-7) Discovered from Genetically Encoded Bicyclic Peptide Libraries
- 8 September 2026
- journal article
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 148 (44) , 48042-48053
Abstract
Glycan-binding proteins (GBPs) are among the most difficult drug targets, limiting clinical progress against therapeutically important GBPs. We employed bicyclic genetically encoded libraries (BiGELs), produced by the chemical modification of phage-displayed peptide libraries with twofold symmetric linchpins, to discover inhibitors of therapeutically relevant Siglec-7:GD3 interactions. Next-generation sequencing (NGS) analysis of BiGEL panning against Siglec-7 yielded 815 candidates, of which 23 hits yielded KD = 1–100 μM, as determined by surface plasmon resonance (SPR). Competitive enzyme-linked immunosorbent assays (ELISA) identified leads that disrupted the Siglec-7:GD3 interaction with IC50 = 3-300 μM. Machine learning models trained on NGS datasets identified additional inhibitors with equivalent potencies. Alanine scans of 8c (SWCRPATVNC, IC50 = 3.8 μM) and 12c (SFCHYPTHVC, IC50 = 11 μM) identified residues crucial for activity. Ring reshaping studies of 8c highlighted the critical role of bicyclic topology, yielding analog 46e (SAAAAAWCRPATVNC, IC50 = 9.5 μM), which was further evolved into 67e (STVTQHWCRPATVNC). The multivalent display of lead bicycles alongside ∼100 glycans in a Liquid Glycan Array (LiGA) enabled the comparison of binding to Siglec-7-expressing cells. LiGA assays confirmed the binding of the bicycles to Siglec-7 but revealed considerable nonspecific interactions with receptor-negative cells. Saturation transfer difference nuclear magnetic resonance (STD-NMR) spectroscopy revealed that 46e binds to Siglec-7 at a site distinct from the V-Ig domain, suggesting inhibition through an allosteric site. Together, these results demonstrate that BiGEL enables the discovery of bicyclic peptides for undruggable Siglec targets, but highlights future challenges in molecular discoveries that aim to identify small, noncarbohydrate inhibitors of GBPs.Keywords
Funding Information
- Canada Foundation for Innovation
- Natural Sciences and Engineering Research Council of Canada (NSERC) (RGPIN-2022-04484)
- Canadian Institutes of Health Research (CIHR) (CIHR FRN: 168961)
- NSERC Accelerator supplement
This publication has 57 references indexed in Scilit:
- The glycoimmune checkpoint receptor Siglec-7 interacts with T-cell ligands and regulates T-cell activationJournal of Biological Chemistry, 2023
- Discovery of Selective and Orally Available Galectin-1 InhibitorsJournal of Medicinal Chemistry, 2023
- Selective oligosaccharide recognition with phenylboronic acid through Cu(I)-catalysed click imprinted surfacesMaterials Today Chemistry, 2022
- Glycosylation in cancer: Selected roles in tumour progression, immune modulation and metastasisCellular Immunology, 2018
- Rapid Discovery of Potent and Selective Glycosidase-Inhibiting De Novo PeptidesCell Chemical Biology, 2017
- Design, Synthesis, and Biological Evaluation of Small, High-Affinity Siglec-7 Ligands: Toward Novel Inhibitors of Cancer Immune EvasionJournal of Medicinal Chemistry, 2017
- Therapeutic Targeting of Siglecs using Antibody- and Glycan-Based ApproachesTrends in Pharmacological Sciences, 2015
- Synthesis and biological evaluation of 9-N-oxamyl sialosides as Siglec-7 ligandsBioorganic & Medicinal Chemistry, 2015
- Peptide therapeutics: current status and future directionsDrug Discovery Today, 2015
- A monosaccharide-modified peptide phage library for screening of ligands to carbohydrate-binding proteinsBioorganic & Medicinal Chemistry Letters, 2013